Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Will lower prices for genomic tests raise medical costs?

Peter Ubel, MD
Conditions
September 3, 2014
41 Shares
Share
Tweet
Share

The first time scientists sequenced a person’s entire genome, it took more than a decade and cost hundreds of millions of dollars. Currently, such sequencing takes less than twenty-four hours and costs less than $5,000.

To put that into perspective, Myriad Genetics charges $3,000 to test for mutations in just two genes associated with breast cancer. The days of affordable genomic sequencing are rapidly approaching. But will such testing bankrupt us?

In most consumer markets, lower prices are a boon to consumer budgets. In the 1950s, for example, Americans spent over 30% of their income on food. But with food production becoming more efficient, that  percent has been cut in half. Like we learned in Econ 101, produce food – or computers or clothing — for less money, and people will spend less money on those goods.

cost-per-genome

But that straightforward economic truth does not necessarily hold when it meets the crooked logic of the American health care system. Consider what happened to health care costs when old-fashioned gallbladder surgery was overtaken by laparoscopy cholecystectomy. In the old-fashioned approach, the surgeon would make a sizeable incision in the patient’s upper belly (right under the rib cage on the right side) and remove the gallbladder,  leaving the patient with impressive scars and several days in the hospital before he or she recovered enough to go home. With the newer laparoscopic approach, surgeons make a few tiny incisions, sneak a laparoscope through one of the openings to remove the gallbladder, leaving patients with a few butterfly Band-Aids and a quick return home. By substantially shortening the hospital stay, this laparoscopic approach was much cheaper than its predecessor. So we must have saved money on gallbladder surgery, right?

Wrong. Because the new procedure was safer, many patients who were previously too risky to operate on were now fair surgical game, as well as those with mild gallbladder disease who had previously been treated with a “tincture of time” (meaning the physician would wait to see if their symptoms would resolve without surgical intervention). As a result of the safety of this procedure, the rate of gallbladder surgery skyrocketed  more than 20% after physicians adopted laparoscopy, more than wiping out the cost savings of the new approach.

Genomic testing may raise medical expenses for a similar reason. As testing becomes less expensive, genomic sequencing can be utilized by an ever broader swath of patients. Moreover, unlike laparoscopic cholecystectomy, which definitively treats a specific illness, genomic sequencing can be used to screen for unknown illness or risk factors.  Laparoscopic cholecystectomy is the end of treatment for most people with gallbladder disease. Genomic sequencing is the beginning of a diagnostic and treatment cascade for many people who receive such tests.  A suspicious mutation may launch further testing to see if the mutation is a harbinger of hidden illness.

Some experts contend that genomic sequencing will lower costs when it helps to tailor therapy to those patients most likely to respond to treatment. Genetic testing may indicate whether a patient’s tumor is responsive to targeting chemotherapy. This would theoretically save money, if patients lacking the right genomic signature are spared an expensive and ineffective treatment. However, such cost savings will only come to fruition if clinicians withhold such treatments from their patients, which is not guaranteed to happen, especially if the genetic information is imperfect and some unidentifiable (if small) subset of that population would potentially respond to treatment.

Furthermore, if new treatments are only available to targeted populations of patients, the market for such products will be reduced and industry will likely respond by raising prices. Research and development costs are no smaller for treatments aimed at small populations than ones targeted at large populations. In fact, they might even more expensive, because it is harder to recruit patients for clinical trials which raises the cost of such testing. Consequently, manufacturers must recoup their costs over a smaller population of patients, thereby raising per-patient costs.

An extreme example of this phenomenon is the orphan drug industry, which develops interventions for diseases or conditions affecting no more than 200,000 people. Prices of these interventions often exceed $150,000 to $200,000 per patient. If genomic testing helps target interventions more efficiently, it could turn many more conditions into orphan diseases.

To fully realize the promise of less expensive genomic testing, we may need to take measures to limit the number of people receiving such tests or the price of interventions targeted to people with uncommon mutations.

Peter Ubel is a physician and behavioral scientist who blogs at his self-titled site, Peter Ubel and can be reached on Twitter @PeterUbel.  He is the author of Critical Decisions: How You and Your Doctor Can Make the Right Medical Choices Together. This article originally appeared in Forbes.

Prev

The cheapest prescription that's most beneficial to patients

September 3, 2014 Kevin 7
…
Next

Beware your doctor's knee-jerk reflex: 3 questions to ask

September 3, 2014 Kevin 10
…

Tagged as: Genetics

Post navigation

< Previous Post
The cheapest prescription that's most beneficial to patients
Next Post >
Beware your doctor's knee-jerk reflex: 3 questions to ask

More by Peter Ubel, MD

  • Clinicians shouldn’t be punished for taking care of needy populations

    Peter Ubel, MD
  • Patients alone cannot combat high health care prices

    Peter Ubel, MD
  • Is the FDA too slow to handle the pandemic?

    Peter Ubel, MD

More in Conditions

  • Lazarus: the dead man brought back to life

    William Lynes, MD
  • The psychoanalytic hammer: lessons in listening and patient-centered care

    Greg Smith, MD
  • 5 essential tips to help men prevent prostate cancer

    Kevin Jones, MD
  • Changing the pediatric care landscape: Integrating behavioral and mental health care

    Hilary M. Bowers, MD
  • Unlocking the secret to successful weight loss: Curiosity is the key

    Franchell Hamilton, MD
  • The teacher who changed my life through reading

    Raymond Abbott
  • Most Popular

  • Past Week

    • The real cause of America’s opioid crisis: Doctors are not to blame

      Richard A. Lawhern, PhD | Meds
    • The struggle to fill emergency medicine residency spots: Exploring the factors behind the unfilled match

      Katrina Gipson, MD, MPH | Physician
    • Healing the damaged nurse-physician dynamic

      Angel J. Mena, MD and Ali Morin, MSN, RN | Policy
    • What is driving physicians to the edge of despair?

      Edward T. Creagan, MD | Physician
    • Beyond the disease: the power of empathy in health care

      Nana Dadzie Ghansah, MD | Physician
    • Deaths of despair: an urgent call for a collective response to the crisis in U.S. life expectancy

      Mohammed Umer Waris, MD | Policy
  • Past 6 Months

    • The hidden dangers of the Nebraska Heartbeat Act

      Meghan Sheehan, MD | Policy
    • The real cause of America’s opioid crisis: Doctors are not to blame

      Richard A. Lawhern, PhD | Meds
    • Nobody wants this job. Should physicians stick around?

      Katie Klingberg, MD | Physician
    • The vital importance of climate change education in medical schools

      Helen Kim, MD | Policy
    • The fight for reproductive health: Why medication abortion matters

      Catherine Hennessey, MD | Physician
    • Resetting the doctor-patient relationship: Navigating the challenges of modern primary care

      Jeffrey H. Millstein, MD | Physician
  • Recent Posts

    • Breaking free from gaslighting [PODCAST]

      The Podcast by KevinMD | Podcast
    • The pros and cons of using ChatGPT for your health care needs

      Liudmila Schafer, MD | Tech
    • Dr. Glaucomflecken for president!

      Aaron Morgenstein, MD & Amy Bissada, DO & Corinne Sundar Rao, MD | Physician
    • What is driving physicians to the edge of despair?

      Edward T. Creagan, MD | Physician
    • Do residents deserve the title of physician?

      Anonymous | Physician
    • A new era of collaboration between AI and health care professionals

      Harvey Castro, MD, MBA | Tech

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 4 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

CME Spotlights

From MedPage Today

Latest News

  • How Did Pulse Oximeters Perform in Black Kids?
  • Coffee and Heart Function; Ionizing Radiation and CVD
  • Health Inequity Should Be Labeled as a 'Never Event'
  • Healing the Damaged Nurse-Physician Dynamic
  • Doc Moms, Mind the Gap -- $3M Earning Difference by Sex

Meeting Coverage

  • Switch to IL-23 Blocker Yields Deep Responses in Recalcitrant Plaque Psoriasis
  • Biomarkers of Response With Enfortumab Vedotin in Advanced Urothelial Cancer
  • At-Home Topical Therapy for Molluscum Contagiosum Gets High Marks
  • Outlook for Itchy Prurigo Nodularis Continues to Improve With IL-31 Antagonist
  • AAAAI President Shares Highlights From the 2023 Meeting
  • Most Popular

  • Past Week

    • The real cause of America’s opioid crisis: Doctors are not to blame

      Richard A. Lawhern, PhD | Meds
    • The struggle to fill emergency medicine residency spots: Exploring the factors behind the unfilled match

      Katrina Gipson, MD, MPH | Physician
    • Healing the damaged nurse-physician dynamic

      Angel J. Mena, MD and Ali Morin, MSN, RN | Policy
    • What is driving physicians to the edge of despair?

      Edward T. Creagan, MD | Physician
    • Beyond the disease: the power of empathy in health care

      Nana Dadzie Ghansah, MD | Physician
    • Deaths of despair: an urgent call for a collective response to the crisis in U.S. life expectancy

      Mohammed Umer Waris, MD | Policy
  • Past 6 Months

    • The hidden dangers of the Nebraska Heartbeat Act

      Meghan Sheehan, MD | Policy
    • The real cause of America’s opioid crisis: Doctors are not to blame

      Richard A. Lawhern, PhD | Meds
    • Nobody wants this job. Should physicians stick around?

      Katie Klingberg, MD | Physician
    • The vital importance of climate change education in medical schools

      Helen Kim, MD | Policy
    • The fight for reproductive health: Why medication abortion matters

      Catherine Hennessey, MD | Physician
    • Resetting the doctor-patient relationship: Navigating the challenges of modern primary care

      Jeffrey H. Millstein, MD | Physician
  • Recent Posts

    • Breaking free from gaslighting [PODCAST]

      The Podcast by KevinMD | Podcast
    • The pros and cons of using ChatGPT for your health care needs

      Liudmila Schafer, MD | Tech
    • Dr. Glaucomflecken for president!

      Aaron Morgenstein, MD & Amy Bissada, DO & Corinne Sundar Rao, MD | Physician
    • What is driving physicians to the edge of despair?

      Edward T. Creagan, MD | Physician
    • Do residents deserve the title of physician?

      Anonymous | Physician
    • A new era of collaboration between AI and health care professionals

      Harvey Castro, MD, MBA | Tech

MedPage Today Professional

An Everyday Health Property Medpage Today iMedicalApps
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Will lower prices for genomic tests raise medical costs?
4 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...